Phase I study of radiochemotherapy with gemcitabine in invasive bladder cancer
Abstract
Tolerability to gemcitabine radiochemotherapy was evaluated in 33 patients with inoperable, locally advanced transitional-cell bladder cancers. The dose of 75 mg/m2 gemcitabine once a week, concurrently with standard radiotherapy of 60 Gy/6 weeks, was found to be acceptable. Eighty-one percentage of 3-year local progression-free survival suggests efficiency warranting further...
Paper Details
Title
Phase I study of radiochemotherapy with gemcitabine in invasive bladder cancer
Published Date
Mar 1, 2012
Journal
Volume
102
Issue
3
Pages
412 - 415
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History